Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 03 - 01 tags : Approval save search
Algoma Steel Group Announces Approval of Normal Course Issuer Bid
Published: 2022-03-01 (Crawled : 23:00) - globenewswire.com
ASTL | $7.74 -4.21% -4.39% 750K
|
Manufacturing
|
| O: -3.21%
H: 11.38%
C: 9.39%
approval group
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM (filgrastim-ayow)
Published: 2022-03-01 (Crawled : 22:00) - biospace.com/
AMRX | $5.37 -0.92% -0.93% 1.8M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
approval biosimilar
FLYHT Receives TSX Venture Exchange Approval for Acquisition of CrossConsense
Published: 2022-03-01 (Crawled : 13:30) - flyht.com
FLYLF | $0.4186 -3.91% 310
|
Electronic Technology
|
| O: 6.64%
H: 0.0%
C: 0.0%
acquisition approval
Otis Receives CNMV Approval of Voluntary Public Tender Offer for Remaining Interest in Zardoya Otis
Published: 2022-03-01 (Crawled : 12:30) - prnewswire.com
OTIS | News | $96.29 1.24% 0.0% 2M
|
Producer Manufacturing
|
| O: 1.32%
H: 0.18%
C: -0.88%
ema approval
HUTCHMED Receives Approval to Commercialize ELUNATE® in MacauFirst homegrown innovative medicine approved in Macau based on China clinical data
Published: 2022-03-01 (Crawled : 11:00) - biospace.com/
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: 0.0%
elunate approval china commercialization
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
Published: 2022-03-01 (Crawled : 09:00) - biospace.com/
LEGN | News | $47.07 1.91% 1.87% 750K
|
Health Technology
|
| O: 4.59%
H: 0.0%
C: -7.26%
treatment fda fda approval car-t approval cel therapy
HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau
Published: 2022-03-01 (Crawled : 09:00) - globenewswire.com
HCM | $16.96 2.79% 2.71% 150K
|
Health Technology
|
| O: 1.17%
H: 4.14%
C: 2.64%
BGNE | $131.15 1.26% 1.24% 150K
|
Health Technology
|
| O: 1.97%
H: 0.0%
C: 0.0%
elunate approval commercialization
CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
Published: 2022-03-01 (Crawled : 01:00) - prnewswire.com
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: 22.61%
H: 0.0%
C: 0.0%
treatment fda biopharma fibrosis approval cel
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.